Skip to content
Homepage
Author:
Sixty Degrees Pharmaceuticals
Posted Date:
August 14, 2026
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
Sixty Degrees Pharmaceuticals
August 14, 2026
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
Sixty Degrees Pharmaceuticals
July 30, 2026
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
Sixty Degrees Pharmaceuticals
July 29, 2026
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
Sixty Degrees Pharmaceuticals
July 11, 2026
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
Sixty Degrees Pharmaceuticals
July 1, 2026
